| Expression pattern: |
DN |
| Associated gene: |
ENO1, FBXW7, H3K18la, CCNA2 |
| Associated microRNA: |
- |
| Biological function: |
Suppresses malignant proliferation and migration; inhibits glycolysis and intracellular lactate accumulation; suppresses tumor growth in vitro and in vivo. |
| Molecular mechanism: |
circBARD1 physically interacts with ENO1 and facilitates FBXW7-mediated ubiquitination and proteasomal degradation of ENO1, thereby inhibiting glycolysis/lactate and suppressing H3K18 lactylation-driven CCNA2 transcription. |
| Biological pathway or process: |
glycolysis (inhibits); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); ubiquitination (promotes); other pathway/process (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; Bioinformatics Analysis; RT-qPCR; Sanger Sequencing; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Western Blot; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; IHC (Immunohistochemistry) |
| Clinical significance: |
Downregulation was significantly linked to advanced tumor stage and low prognosis. |
| Description: |
In human bladder cancer, circBARD1 is down-regulated and acts as a tumor suppressor by inhibiting proliferation and migration. Mechanistically, circBARD1 binds ENO1 and promotes FBXW7-mediated ubiquitination/proteasomal degradation of ENO1, reducing glycolysis/lactate, suppressing H3K18 lactylation and thereby downregulating CCNA2 transcription, which limits tumor growth in vitro and in a xenograft model. |
| Confidence score: |
0.849 |